<DOC>
	<DOC>NCT01439204</DOC>
	<brief_summary>The purpose of this study is to determine whether the blood levels of Abatacept (BMS-188667) drug product manufactured at Lonza Biologics and the Devens, MA facility of Bristol-Myers Squibb are comparable in healthy subjects</brief_summary>
	<brief_title>Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb</brief_title>
	<detailed_description>Primary Purpose of this study is to compare the pharmacokinetic (PK) of Abatacept (BMS-188667) manufactured at Lonza relative to Abatacept (BMS-188667) manufactured at Devens, MA facility following a single intravenous infusion of 750 mg in healthy subjects</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations Body weight will be between 60 and 100 kg, inclusive Any significant acute or chronic medical illness Any major surgery within 4 weeks of study drug administration Smoking more than 10 cigarettes per day Recent (within 6 months of study drug administration) drug or alcohol abuse. Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus1, Human Immunodeficiency Virus2 antibody History of any significant drug allergy or asthma Women who are pregnant or breastfeeding and/or unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>